Gujarat, India
Gujarat, India

Time filter

Source Type

Patel A.H.,Torrent Research Center | Patel J.K.,P.A. College | Patel K.N.,P.A. College
International Journal of Pharmaceutical Sciences | Year: 2010

The use of first order derivative spectroscophotometry allowed simultaneous determination of domperidone and rabeprazole sodium, in fixed dose combination products. The absorbance values at 253.2 nm and 266.4 nm of first derivative spectrum was used for the estimation of domperidone and rabeprazole sodium, respectively without mutual interference. This method obeyed beer's law in the concentration range of 9-45 μg/ml and 6-30 μg/ml for both domperidone and rabeprazole sodium, respectively. The results of analysis have been validated statistically and recovery studies confirmed the accuracy of the proposed method.


Patel A.H.,Torrent Research Center | Patel J.K.,P.A. College | Patel K.N.,P.A. College
International Journal of Pharmaceutical Sciences | Year: 2010

The use of first order derivative spectroscophotometry allowed simultaneous determination of domperidone and rabeprazole sodium, in fixed dose combination products. The absorbance values at 253.2 nm and 266.4 nm of first derivative spectrum was used for the estimation of domperidone and rabeprazole sodium, respectively without mutual interference. This method obeyed beer's law in the concentration range of 9-45 μg/ml and 6-30 μg/ml for both domperidone and rabeprazole sodium, respectively. The results of analysis have been validated statistically and recovery studies confirmed the accuracy of the proposed method.


Joshi D.,Torrent Research Center | Shiwalkar A.,Torrent Research Center | Cross M.R.,Veeda Clinical Research | Sharma S.K.,Veeda Clinical Research | And 2 more authors.
Heart | Year: 2010

Background: Reduced exercise capacity in diabetics has been attributed to limitations in cardiac function and microvascular dysfunction leading to impaired oxygen supply and nutritive perfusion to exercising muscles. Objective: To study changes in cardiac function and microvascular utilisation during exercise in diabetic individuals compared to age-matched controls. Methods: Diabetics with glycosylated haemoglobin (HbA1c) <8 (n=31), diabetics with HbA1c ≥8 (n=38) and age-matched non-diabetic controls (n=32) performed exercise at 50 W for 10 minutes followed by recovery, with continuous monitoring of cardiac function by impedance cardiography and regional flow and oxygen saturation by laser Doppler and white light spectroscopy. Results: In the diabetics, cardiac reserve during exercise and cardiac overshoot during recovery are significantly reduced because of reduction in capacity to increase stroke volume. Regional flow to the exercising muscle is reduced and there is also disproportionately greater desaturation of the regional flow. Abnormalities in cardiac function and regional perfusion are related to the severity of diabetes. Conclusion: Cardiac response to exercise is attenuated significantly in diabetic individuals. Simultaneously, there is impairment in the regional distribution. These changes could be the harbinger of reduced exercise capacity in diabetics.


Tiwari O.P.,Institute of Pharmacy | Bhattamisra S.K.,Torrent Research Center | Singh P.N.,Banaras Hindu University
BioScience Trends | Year: 2010

The present study was undertaken to evaluate in vivo anti-aggressive potential of a standardized extract of Marsilea minuta Linn. (Marsileaceae). The standardized extract of Marsilea minuta was evaluated for its potential effects against defensive and offensive aggressive behavior models of rodents. Marsilea minuta extract was orally administered at three dose levels (100, 200, and 400 mg/kg BW) once daily for 14 consecutive days as a suspension in polyethylene glycol (PEG), diazepam (2.5 mg/kg, p.o.) was used as a standard anti-aggressive agent. Control group animals were given an equal volume of vehicle (10%, v/v, PEG suspension). Anti-aggressive activity was evaluated using the following validated models of aggression, viz.: foot shock-induced aggression, isolation-induced aggression and resident-intruder aggression, in rodents. As a result, Marsilea minuta extract showed dose dependant anti-aggressive activity in the aforementioned, validated models of aggression. This suggests that the extract from Marsilea minuta has a promising anti-aggressive activity qualitatively comparable to that of diazepam.


PubMed | KB Institute of Pharmaceutical Education and Research, Torrent Research Center, Navsari Agricultural University, Zydus Research Center and University of Tennessee Health Science Center
Type: Journal Article | Journal: Indian journal of pharmacology | Year: 2015

To study the effects of two different classes of drugs in sephadex-induced lung inflammation using rats and explore the potential mechanism (s).Effects of dexamethasone (0.3 mg/kg, p.o.) and rosiglitazone (10 mg/kg, p.o.) treatments were evaluated up to 3 days in sephadex challenged rats. 72 h postsephadex administration, broncho-alveolar lavage fluid (BALF) was collected for cell count and cytokine estimation. Lung tissues were harvested for gene expression and histopathology.Dexamethasone treatment resulted in significant inhibition of lymphocytes, monocytes, eosinophils and neutrophils, whereas rosiglitazone inhibited eosinophils and neutrophils only. Further, dexamethasone reduced the elevated levels of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) after sephadex challenge while rosiglitazone significantly reduced the PGE2 levels without altering LTB4 in the BALF. Hydroxyproline content in rat lung homogenate was significantly reduced with dexamethasone treatment but not with rosiglitazone. Both the drugs were found to suppress matrix metallo proteinase 9, whereas only dexamethasone showed inhibition of tumor necrosis factor-alpha and up-regulation of tissue inhibitor of metalloproteinase 3 (TIMP-3) expression and preserved the broncho-alveolar microstructure.Our results revealed that up-regulation of TIMP-3 corroborated well with dexamethasone mediated inhibition of collagen degradation and restoration of alveolar micro-architecture.


Gupta Y.,Pharmaceutics Research Projects Laboratory | Gupta Y.,Torrent Research Center | Ganesh N.,Jawaharlal Nehru Cancer Hospital and Research Center | Kohli D.V.,Pharmaceutics Research Projects Laboratory | Jain S.K.,Pharmaceutics Research Projects Laboratory
Current Nanoscience | Year: 2011

The aim of the present study is to investigate the vitamin B12 conjugated doxorubicin loaded sterically stabilized liposomes for tumor targeting. Plain and sterically stabilized liposomes were prepared by modified ethanol injection method followed by remote loading of doxorubicin by ammonium sulphate gradient method. The sterically stabilized liposomes were coupled with vitamin B12 using post insertion technique. The average size of liposomes was found to be in range 105-128 nm and maximum entrapment efficiency was found to be 89.3-94.5%. In vitro cell binding of SL-VB12 exhibits 6.28 folds higher binding to B16F10 melanoma cells in comparison to sterically stabilized liposomes. In vitro cytotoxicity study was conducted on B16F10 melanoma cells. SL-VB12 demonstrated strongest cytotoxicity to the tumor cells as compared to non targeted formulations i.e. PL and SL confirming that SL-VB12 was effectively taken up by tumor cells. The pharmacokinetic, tissue distribution and tumor growth inhibition studies were carried out followed by intravenous administration of liposomal formulations in C57BL/6 mice carrying B16F10 melanoma tumor. The half-life of SL-VB12 and SL was about 7.2 and 8.5 fold higher than that of free DOX, respectively. Accumulation of SL-VB12 in the tumor tissue was 18.9 and 2 times higher as compared to free DOX and SL respectively after 8 hours. SL-VB12 at the dose of 5 mg DOX/kg resulted in effective retarda- tion of tumor growth. The liposomal formulation also prolong the survival time of mice as compared to free drug. Results indicate that vi- tamin B12 coupled liposomes bearing doxorubicin are significantly active against primary tumor than non targeted liposomes. In sum- mary, our study indicated that the vitamin B12 coupled sterically stabilized liposomes (SL-VB12) could be used as a targeted carriers to facilitate the delivery of the encapsulated anticancer drugs into tumor cells by receptor mediated way. © 2011 Bentham Science Publishers Ltd.


Mane U.R.,M. S. University of Baroda | Mane U.R.,Torrent Research Center | Li H.,East China University of Science and Technology | Huang J.,East China University of Science and Technology | And 5 more authors.
Bioorganic and Medicinal Chemistry | Year: 2012

Plasmodium falciparum cysteine protease falcipain-2 (FP-2) is a promising target for antimalarial chemotherapy and inhibition of this protease affects the growth of parasite adversely. A series of pyrido[1,2-a]pyrimidin-4-ones were synthesized and evaluated for their in vitro FP-2 inhibitory potential. Compounds (14,17) showed excellent FP-2 inhibition and can serve as lead compounds for further development of potent FP-2 inhibitors as potential antimalarial drugs. © 2012 Elsevier Ltd. All rights reserved.


Mane U.R.,M. S. University of Baroda | Mane U.R.,Torrent Research Center | Mohanakrishnan D.,Malaria Research Laboratory | Sahal D.,Malaria Research Laboratory | And 3 more authors.
European Journal of Medicinal Chemistry | Year: 2014

Novel pyrido[1,2-a]pyrimidin-4-ones have been synthesized and evaluated for their antimalarial activity by SYBR Green I assay against erythrocytic stages of chloroquine (CQ) sensitive Pf 3D7 strain. The antimalarial screening of 42 different compounds revealed that 3-Fluorobenzyl(4-oxo-4H-pyrido [1,2-a]pyrimidin-3-yl)carbamate (21, IC50 value 33 μM) and 4-Oxo-N-[4-(trifluoromethyl)benzyl]-4H-pyrido[1,2-a]pyrimidine-3-carboxamide (37, IC50 value 37 μM) showed moderate antimalarial activity. Cytotoxicity study was performed against mammalian cell line (Huh-7) by using the MTT assay for the moderately active compounds. Structural activity relationship (SAR) studies displayed that B-ring unsubstituted pyrido[1,2-a]pyrimidine scaffold is responsible for the antimalarial activities of the evaluated derivatives. This SAR based antimalarial screening supported that pyrido[1,2-a]pyrimidin-4-one can be considered as a lead heterocyclic structure for further development of more potent derivatives for antimalarial activity. © 2014 Elsevier Masson SAS. All rights reserved.


Patel H.B.,Torrent Research Center | Patel H.B.,Saurashtra University | Mohan A.,Shasun Pharmaceuticals | Joshi H.S.,Saurashtra University
Journal of AOAC International | Year: 2011

A simple RP-ultra-performance LC method was developed and validated for determination of impurities related to torsemide tablets. The rapid method provided adequate separation of all known related impurities and degradation products. Separation was achieved on a Zorbax SB-C18 column (50 × 4.6 mm id, 1.8 μm particle size) with binary gradient elution, and detection was performed at 288 nm. The drug product was subjected to oxidative, hydrolytic, photolytic, and thermal stress conditions to prove the specificity of the proposed method. The linearity and recovery were investigated for known impurities in the range of 0.025 to 1.0%, with respect to the drug concentration in the prepared sample. The linearity of the calibration curve for each of the impurities and torsemide was found to be very good (r 2 > 0.999). Relative response factors for each of the known impurities were established by the slope ratio method from the linearity study.


Chokshi N.A.,Torrent Research Center
Journal of Generic Medicines | Year: 2013

Prior to Pediatric Research Equity Act's enactment, Food and Drug Administration had approved several suitability petitions to permit abbreviated new drug applications to be submitted for drugs that had a different active ingredient, dosage form, or route of administration than their reference-listed drugs. Pediatric Research Equity Act does not impose pediatric assessment requirements on abbreviated new drug applications for generic drugs. However, abbreviated new drug applications submitted under an approved suitability petition under section 505(j)(2)(C) of the Act and the said difference from the reference-listed drugs are subject to the pediatric assessment requirements that Pediatric Research Equity Act imposes. In the federal notice dated 23 February 2007, Food and Drug Administration explained that the approval of 128 suitability petitions was being withdrawn because abbreviated new drug applications were never submitted and Pediatric Research Equity Act requires that all applications submitted on or after 1 April 1999, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration containing an assessment of the safety and effectiveness of the drug for the claimed indications in relevant pediatric subpopulations unless the requirement is waived or deferred. Underlining information in this article helps in understating the Pediatric Research Equity Act, pediatric assessment for suitability petitions, pediatric review committee and its role, types of pediatric waivers, and its importance in suitability petitions. Also there are several examples provided for the Pediatric Research Equity Act assessment in recently filed suitability petitions by the various firms. © SAGE Publications.

Loading Torrent Research Center collaborators
Loading Torrent Research Center collaborators